Physician profile
John A Co
NPI 1588620199
$8,000.54
in general payments reported to CMS, 2019-2025
27 companies · $783 in 2025
The $783 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,348 · 2020: $1,066 · 2021: $1,213 · 2022: $1,415 · 2023: $1,313 · 2024: $863 · 2025: $783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,871 · Education: $87.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,871.40 |
| Education | $87.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,012.26 | 2019-2025 | |
| Boston Scientific Corporation | $816.32 | 2019-2023 | Watchman |
| Merck Sharp & Dohme LLC | $677.07 | 2021-2025 | Verquvo |
| Amgen INC. | $650.28 | 2019-2025 | Repatha, Repatha, Krystexxa |
| Janssen Pharmaceuticals, INC | $640.79 | 2019-2023 | Xarelto |
| Novo Nordisk INC | $638.81 | 2021-2025 | Wegovy, Ozempic |
| E.R. Squibb & Sons, L.L.C. | $554.03 | 2019-2025 | Pomalyst, Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $496.63 | 2019-2024 | Wainua |
| Pfizer INC. | $378.07 | 2019-2025 | |
| Amarin Pharma, INC. | $350.57 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $213.76 | 2019-2023 | Livalo |
| Heartflow, INC. | $212.07 | 2022-2025 | Ffrct |
| Edwards Lifesciences Corporation | $197.44 | 2022 | |
| Medtronic Vascular, INC. | $196.05 | 2020 | |
| Cleerly, INC. | $180.89 | 2025 | Cleerly Ischemia, Cleerly Labs |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $178.87 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $124.99 | 2019 | |
| Atricure, INC. | $123.89 | 2020 | |
| Esperion Therapeutics, INC. | $91.13 | 2020-2024 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $82.30 | 2022 | |
| Arbor Pharmaceuticals, INC. | $42.08 | 2019-2021 | |
| Gilead Sciences, INC. | $38.22 | 2019 | |
| Sanofi-Aventis U.S. LLC | $28.77 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.50 | 2021 | |
| Macrogenics, INC. | $17.68 | 2022 | |
| Abbott Laboratories | $15.99 | 2022 | |
| Azurity Pharmaceuticals, INC. | $15.08 | 2023 | Edarbi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Co listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.